ClinPGx Blog

Sign in Subscribe

Latest — May 13, 2026

Correction to CPIC Guideline for TPMT, NUDT15 and Thiopurines

A correction to Table 1 of the "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update" was published in Clinical Pharmacology and Therapeutics. An individual carrying one no function allele plus one decreased function allele is an Intermediate Metabolizer (IM)

More issues

Updates to the CPIC Database and API

We want to inform everyone of some things that are changing (and some things that are not) in the CPIC database and API. CPIC and ClinPGx CPIC is now part of ClinPGx. The standalone CPIC site will retire soon, but all its content will move to ClinPGx. Visiting cpicpgx.org

CPIC is moving to the ClinPGx website

The Clinical Pharmacogenetics Implementation Consortium is moving to the ClinPGx website. All CPIC information will still be available in a similar format. All current and published CPIC URLs should re-direct to equivalent pages on the ClinPGx website, so existing bookmarks and links should not break. We plan for CPIC URLs

New and Updated Antipsychotics Pathways

CPIC is currently evaluating evidence on antipsychotics and CYP2D6, CYP3A4 and CYP2C19 for the development of guidelines. To support this ClinPGx curators have expanded our set of antipsychotics pathways; updating and developing some of our in progress pathways and curating some new ones.

CPIC Guideline Update for TPMT, NUDT15 and Thiopurines

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update has been published in Clinical Pharmacology and Therapeutics (PMID:41618934). The guideline contains multiple updates to the previous recommendations for adjusting the starting doses of azathioprine, mercaptopurine and thioguanine according to the

New PharmCAT release

Highlights of the latest releases (v3.1.0- v3.1.1) are: * CPIC function and phenotype assignments are used to provide genotype-level guidance from all sources including DPWG and FDA. For a detailed blog see, Genotype-Phenotype Mapping for Guideline and Drug Label Curation. * Allele definitions are up to date to

Genotype-Phenotype Mapping for Guideline and Drug Label Curation

ClinPGx now uses CPIC/ClinPGx allele function and phenotype mappings and terms for guideline and drug label curation, including the interactive genotype picker tools on DPWG guideline annotation pages. If a DPWG guideline gene is not a CPIC gene, then we will continue to use DPWG mappings based on documents

Updated FDA-approved label for Xeloda (capecitabine)

The FDA-approved label for Xeloda (capecitabine) was updated a week ago to include a boxed warning regarding adverse reactions in patients with complete DPD deficiency and to "Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary." This language is new. The

CPIC Guideline for NAT2 Genotype and Hydralazine Therapy

The CPIC Guideline for NAT2 Genotype and Hydralazine Therapy has been published in the journal Clinical Pharmacology and Therapeutics. This new guideline summarizes and evaluates literature evidence regarding the impact of genetic variants on NAT2's metabolism of hydralazine, a vasodilator typically used in the treatment of resistant hypertension

ClinGen Pharmacogenomics Interpretation Committee Publication on Survey Findings

We are excited to announce the publication of Toward an integrated resource for pharmacogenomics (PGx): Survey findings from the genomic medicine communities (PMID: 40662343) by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC) in Genetics in Medicine. This publication covers the results of the PGxIC’s two needs assessment surveys targeting both